PARP inhibitors in ovarian cancer: Current status and future promise

Gynecologic Oncology

Volumn 133, Issue 2, 2014, Pages 362-369

  Liu, Joyce F ^a   Konstantinopoulos, Panagiotis A ^a   Matulonis, Ursula A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

BRCA; Ovarian cancer; PARP inhibitors

Indexed keywords

AGO 14699; ANTINEOPLASTIC AGENT; AZD 2461; BEVACIZUMAB; BMN 673; BRCA1 PROTEIN; BRCA2 PROTEIN; BUPARLISIB; CARBOPLATIN; CEDIRANIB; CEP 9722; CO 338; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; E 7449; GEMCITABINE; GYRASE INHIBITOR; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; RUCAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; DNA END JOINING REPAIR; DNA REPAIR; DNA REPLICATION; DRUG MECHANISM; GERMLINE MUTATION; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMATIC MUTATION;

BRCA; OVARIAN CANCER; PARP INHIBITORS;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DNA REPAIR; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; INDAZOLES; INDOLES; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84899650704     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.02.039     Document Type: Review

References (64)

1. K. Do, and A.P. Chen Molecular pathways: targeting PARP in cancer treatment Clin Cancer Res 19 2012 977 984
2. C.J. Lord, and A. Ashworth The DNA damage response and cancer therapy Nature 481 2012 287 294
3. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, and E. Lopez et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-Ribose) polymerase Nature 434 2005 913 917
4. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, and T.B. Richardson et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
5. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, and M. Mergui-Roelvink et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA-carriers N Engl J Med 361 2009 123 134
6. J.A. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, and G. Rustin et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N Engl J Med 366 2012 1382 1392
7. Integrated genomic analyses of ovarian cancer Nature 474 2011 609 615
8. J.A. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, and J.S. Gordon et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation Clin Oncol 31 2013 [Suppl.; abstr 5505]
9. M. Rouleau, A. Patel, M.J. Hendzel, S.H. Kaufmann, and G.G. Poirier PARP inhibition: PARP1 and beyond Nat Rev Cancer 10 2010 293 301
10. Patel Ag, Sarkaria Jn, and S.H. Kaufmann Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells Proc Natl Acad Sci U S A 108 8 2011 3406 3411
11. J. Murai, S.Y. Huang, B.B. Das, A. Renaud, Y. Zhang, and J.H. Dorowhow et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res 72 2012 5588 5599
12. K. Alsop, S. Fereday, C. Meldrum, A. DeFazio, C. Emmanuel, and J. George et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J Clin Oncol 30 2012 2654 2663
13. T. Pal, J. Permuth-Wey, J.A. Betts, J.P. Krischer, J. Fiorica, and H. Arango et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 2005 2807 2816
14. B.T. Hennessy, K.M. Timms, M.S. Carey, A. Gutin, L.A. Meyer, and D.D. Flake et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer J Clin Oncol 28 2010 3570 3576
15. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, and K.M. Bell-McGuinn et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
16. K.A. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, and K. Tonkin et al. Olaparib in patients with high grade serous or poorly differentiated ovarian carcinoma or triple negative breast cancer: a phase 2, multicenter, open-label, non-randomized study Lancet Oncol 12 2011 852 861
17. K.P. Pennington, T. Walsh, M.I. Harrell, M.K. Lee, C.C. Pennil, and M.H. Rendi et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas Clin Cancer Res 20 2014 764 775
18. K.P. Pennington, and E.M. Swisher Hereditary ovarian cancer: beyond the usual suspects Gynecol Oncol 124 2012 347 353
19. J. Mateo, M. Ong, D.S. Tan, M.A. Gonzalex, and J.S. de Bono Appraising iniparib, the PARP inhibitor that never was-what must we learn? Nat Rev Clin Oncol 10 2013 688 696
20. A.G. Patel, S.B. De Lorenzo, K.S. Flatten, G.G. Poirier, and S.H. Kaufmann Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro Clin Cancer Res 18 2012 1655 1662
21. S.B. Kaye, J. Lubinski, U. Matulonis, J.E. Ang, C. Gourley, and B.Y. Karlan et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer J Clin Oncol 30 2012 372 379
22. P.C. Fong, T.A. Yap, D.S. Boss, C.P. Carden, M. Mergui-Roelvink, and C. Gourley et al. Poly(ADP-ribose) polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2010 2512 2519
23. B. Norquist, K.A. Wurz, C.C. Pennil, R. Garcia, J. Gross, and W. Sakai et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas J Clin Oncol 29 2011 3008 3015
24. C.J. Lord, and A. Ashworth Mechanisms of resistance to therapies targeting BRCA-mutant cancers Nat Med 19 2013 1381 1388
25. J.E. Ang, C. Gourley, C.B. Powell, H. High, R. Shapira-Frommer, and V. Castonguay et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study Clin Cancer Res 19 2013 5485 5493
26. S.F. Bunting, E. Callén, N. Wong, H.T. Chen, F. Polato, and A. Gunn et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks Cell 141 2010 243 254
27. S.F. Bunting, E. Callén, M.L. Kozak, J.M. Kim, N. Wong, and A.J. Lopez-Contreras et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair Mol Cell 46 2012 125 135
28. T. Safra, L. Borgato, M.O. Nicoletto, L. Rolnitzky, S. Pelles-Avraham, and R. Geva et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin Mol Cancer Ther 10 2011 2000 2007
29. J. Balmana, N. Tung, S.J. Isakoff, B. Grana, P.D. Ryan, and R. Rafi et al. Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors J Clin Oncol 30 2012 [suppl; abstr 1009]
30. A. Rajan, C.A. Carter, R.J. Kelly, M. Gutierrez, S. Kummar, and E. Szabo et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors Clin Cancer Res 18 2012 2344 2351
31. J.M. Lee, C.M. Annunziata, J.L. Hays, A.M. Noonan, L.M. Minasian, and J. Zujewski et al. Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062). DNA Repair and Apoptosis 2514 J Clin Oncol 31 2013 [Suppl.; abstr 2514]
32. Ruud van der Noll, Joo Ern Ang, S. Agnes Jager, S. Marchetti, M. Mergui-Roelvink, and J.S. DeBono et al. Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors J Clin Oncol 31 2013 [Suppl.; abstr 2579]
33. A.M. Oza, D. Cibula, A. Oaknin, C.J. Poole, R.H.J. Mathijssen, and G.S. Sonke et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients with platinum-sensitive recurrent serous ovarian cancer: a randomized, open-label phase II study J Clin Oncol 30 2012 [Suppl.; abstr 5001]
34. T.D. Penning, G.D. Zhu, V.B. Gandhi, J. Gong, X. Liu, and Y. Shi et al. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer J Med Chem 52 2009 514 523
35. R. Coleman, M. Sill, and C. Aghajanian et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - a Gynecologic Oncology Group study Society of Gynecologic Oncology Annual Meeting on Women's Cancer 2013 [Abstract LBA5]
36. S. Kummar, A. Chen, J. Ji, Y. Zhang, J.M. Reid, and M. Ames et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in Adults with refractory solid tumors and lymphomas Cancer Res 71 2011 5626 5634
37. P. LoRusso, J. Ji, J. Li, L.K. Heilbrun, G. Shapiro, and E.A. Sausville et al. Phase I study of the safety, pharmacokinetics and pharmacodynamics of the poly(ADP-ribose)polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan (CPT-111) in patients with advanced solid tumors J Clin Oncol 29 2011 [Suppl.: abstract 3000]
38. A.R. Tan, D. Toppmeyer, M.N. Stein, R.A. Moss, M. Gounder, and D.C. Lindquist et al. Phase I trial of veliparib (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors J Clin Oncol 29 2011 [Suppl.: abstract 3041]
39. S. Kummar, J. Ji, R. Morgan, H.J. Lenz, S.L. Puhalla, and C.P. Belani et al. A Phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas Clin Cancer Res 18 2012 1726 1734
40. S. Kummar, R. Kinders, M.E. Gutierrez, L. Rubinstein, R.E. Parchment, and L.R. Phillips et al. Phase 0 clinical trial of the poly(ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies J Clin Oncol 27 2009 2705 2711
41. S. Kummar, A.M. Oza, G.F. Fleming, D. Sullivan, D.R. Gandara, and C. Erlichman et al. Randomized trial of oral cyclophosphamide with or without veliparib, an oral poly (ADP-ribose) polymerase inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high grade serous ovarian cancer J Clin Oncol 30 2012 [Suppl.; abstr 5020]
42. P. Jones, S. Altamura, J. Boueres, F. Ferrigno, M. Fonsi, and C. Giomini et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors J Med Chem 52 2009 7170 7185
43. S.K. Sandhu, W.R. Schelman, G. Wilding, V. Moreno, R.D. Baird, and S. Miranda et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Lancet Oncol 14 2013 882 892
44. M. Ihnen, C. zu Eulenburg, T. Kolarova, J.W. Qi, K. Manivong, and M. Chalukya et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer Mol Cancer Ther 12 2013 1002 1015
45. G. Shapiro, R. Kristeleit, M. Middleton, H. Burris, L.R. Molife, and J. Evans et al. Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors Proceedings of AACR/NCI/EORTC targeted therapies meeting 2013 [abstract 218]
46. R. Kristeleit, H. Burris, P. LoRusso, M. Patel, H. Giordano, and J. Evans et al. Phase I study of continuous oral rucaparib: analysis of patient subgroup with ovarian/peritoneal cancer Proceedings from the European Society of Gynecologic Oncology meeting 2013 [abstract 124]
47. R. Plummer, C. Jones, M. Middleton, R. Wilson, J. Evans, and A. Olsen et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors Clin Cancer Res 14 2008 7917 7923
48. P. Roxburgh, L.R. Molife, A. Gupta, R. Wilson, J. Evans, and N. Cresti et al. A phase I study of oral rucaparib in combination with carboplatin Proceedings from the European Cancer Congress 2013 [abstract 824]
49. N. Coupe, P. Roxburgh, Y. Drew, L.R. Molife, R. Wilson, and J. Spicer et al. Phase I study of oral or intravenous rucaparib in combination with platinum-containing chemotherapeutic regimens: analysis of patients with ovarian or peritoneal cancers Eur Soc of Gyn Onc Proceedings 2013 [abstract 155]
50. Y. Shen, F.L. Rehman, Y. Feng, J. Boshuizen, I. Bajrami, and R. Elliott et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency Clin Cancer Res 19 2013 5003 5015
51. J.S. De Bono, L.A. Mina, M. Gonzalez, N.J. Curtin, E. Wang, and J.W. Henshaw et al. First-in-human trial of the novel PARP inhibitor BMN 673 in patients with solid tumors J Clin Oncol 31 2013 [Suppl.; abstr 2580]
52. L. Tentori, P.M. Lacal, A. Muzi, A.S. Dorio, C. Leonetti, and M. Scarsella et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis Eur J Cancer 43 2007 2124 2133
53. R.S. Bindra, S.L. Gibson, A. Meng, U. Westermark, M. Jasin, and A.J. Pierce et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs Cancer Res 65 24 2005 11597 11604
54. R.S. Bindra, P.J. Schaffer, A. Meng, J. Woo, K. Maseide, and M.E. Roth et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells Mol Cell Biol 24 19 2004 8504 8518
55. N. Chan, and R.G. Bristow "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair Clin Cancer Res 16 18 2010 4553 4560
56. D.C. Hegan, Y. Lu, G.C. Stachelek, M.E. Crosby, R.S. Bindra, and P.M. Glazer Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130 Proc Natl Acad Sci U S A 107 5 2010 2201 2206
57. E. Dean, M.R. Middleton, T. Pwint, H. Swaisland, J. Carmichael, and P. Goodege-Kunwar et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumors Br J Cancer 106 2012 468 474
58. U.A. Matulonis, S. Berlin, P. Ivy, K. Tyburski, C. Krasner, and C. Zarwan et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube and peritoneal cancer 27 2009 5601 5606
59. J.F. Liu, S.M. Tolaney, M. Birrer, G.F. Fleming, M.K. Buss, and S.E. Dahlberg et al. A phase I trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer Eur J Cancer 49 2013 2972 2978
60. I.K. Kolasa, A. Rembiszewska, A. Felisiak, I. Ziolkowska-Seta, M. Murawska, and J. Moes et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients Cancer Biol Ther 8 2009 21 26
61. R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 2009 415 428
62. A. Juvekar, L.N. Burga, H. Hu, E.P. Lunsford, Y.H. Ibrahim, and J. Balmana et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer Cancer Discov 2 2012 1048 1063
63. Y.H. Ibrahim, C. García-García, V. Serra, L. He, K. Torres-Lockhart, and A. Prat et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition Cancer Discov 2 2012 1036 1047
64. J. Murai, S.Y. Huang, A. Renaud, Y. Zhang, J. Ji, and S. Takeda et al. Stereospecific PARP trapping by BMN673 and comparison with olaparib and rucaparib Mol Cancer Ther 13 2014 433 443